{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:19:42Z","timestamp":1793762382990,"version":"4.6.1"},"reference-count":206,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jacc.2025.07.061","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:45:33Z","timestamp":1759211133000},"page":"1065-1087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Fibrinolytic Therapy for Thromboembolic Diseases"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-5611","authenticated-orcid":false,"given":"Sina","family":"Rashedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Hamade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana B.","family":"Pfeferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9567-3253","authenticated-orcid":false,"given":"Luis","family":"Ortega-Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-0513","authenticated-orcid":false,"given":"Parham","family":"Sadeghipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azita H.","family":"Talasaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Monreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2562-1156","authenticated-orcid":false,"given":"Mitchell S.V.","family":"Elkind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0485-2692","authenticated-orcid":false,"given":"Irene M.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros V.","family":"Konstantinides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-5276","authenticated-orcid":false,"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.07.061_bib1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/s-0044-1781451","article-title":"Fibrinolytic agents in thromboembolic diseases: historical perspectives and approved indications","volume":"50","author":"Rashedi","year":"2024","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2025.07.061_bib2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1538-7836.2011.04370.x","article-title":"Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin","volume":"9","author":"Marder","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2025.07.061_bib3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1084\/jem.58.4.485","article-title":"The fibrinolytic activity of hemolytic streptococcI","volume":"58","author":"Tillett","year":"1933","journal-title":"J Exp Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/301214a0","article-title":"Cloning and expression of human tissue-type plasminogen activator cDNA in E coli","volume":"301","author":"Pennica","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2025.07.061_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(03)12113-7","article-title":"Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials","volume":"361","author":"Keeley","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib6","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib7","first-page":"e771","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib8","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacc.2025.07.061_bib9","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2025.07.061_bib10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00445-2018","article-title":"Management appropriateness and outcomes of patients with acute pulmonary embolism","volume":"51","author":"Jimenez","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2025.07.061_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.acvd.2019.09.009","article-title":"Clinical patterns and significance of non-compliance with guideline-recommended treatment of acute pulmonary embolism","volume":"113","author":"Cart","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2025.07.061_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11239-019-01867-0","article-title":"Thrombolysis in hemodynamically unstable patients: still underused: a review based on multicenter prospective registries on acute pulmonary embolism","volume":"48","author":"Zuin","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2025.07.061_bib14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCULATIONAHA.113.005544","article-title":"Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism","volume":"129","author":"Kucher","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.061_bib15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jamacardio.2022.3591","article-title":"Catheter-directed thrombolysis vs anticoagulation in patients with acute intermediate-high-risk pulmonary embolism: the CANARY Randomized Clinical Trial","volume":"7","author":"Sadeghipour","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)61753-4","article-title":"Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial","volume":"379","author":"Enden","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib17","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa1615066","article-title":"Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis","volume":"377","author":"Vedantham","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib18","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib19","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke","volume":"6","author":"Berge","year":"2021","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.jacc.2025.07.061_bib20","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STROKEAHA.118.022606","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.07.061_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.10800","article-title":"Intra-arterial tenecteplase for acute stroke after successful endovascular therapy: the ANGEL-TNK randomized clinical trial","author":"Miao","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib22","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jama.2022.1645","article-title":"Effect of intra-arterial alteplase vs placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke: the CHOICE randomized clinical trial","volume":"327","author":"Renu","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib23","article-title":"Intra-arterial tenecteplase after successful endovascular recanalisation in patients with acute posterior circulation arterial occlusion (ATTENTION-IA): multicentre randomised controlled trial","volume":"388","author":"Hu","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2025.07.061_bib24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/STROKEAHA.124.048846","article-title":"Safety of adjunctive intraarterial tenecteplase following mechanical thrombectomy: the ALLY pilot trial","volume":"56","author":"Zaidi","year":"2025","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.07.061_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/jama.2024.23466","article-title":"Intra-arterial tenecteplase following endovascular reperfusion for large vessel occlusion acute ischemic stroke: the POST-TNK randomized clinical trial","volume":"333","author":"Huang","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jama.2024.23480","article-title":"Intra-arterial urokinase after endovascular reperfusion for acute ischemic stroke: the POST-UK randomized clinical trial","volume":"333","author":"Liu","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib27","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213842","article-title":"Intra-arterial thrombolysis following endovascular recanalization for large vessel occlusion stroke: a systematic review and meta-analysis","volume":"105","author":"Jiang","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.07.061_bib28","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/eurheartj\/ehad734","article-title":"Exercise therapy for chronic symptomatic peripheral artery disease","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"issue":"Suppl 5","key":"10.1016\/j.jacc.2025.07.061_bib30","doi-asserted-by":"crossref","first-page":"v152","DOI":"10.1093\/annonc\/mdv296","article-title":"Central venous access in oncology: ESMO Clinical Practice Guidelines","volume":"26","author":"Sousa","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jacc.2025.07.061_bib31","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1200\/JCO.2012.45.5733","article-title":"Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Schiffer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacc.2025.07.061_bib32","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jvir.2010.09.002","article-title":"TROPICS 1: a phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional central venous catheters","volume":"21","author":"Gabrail","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib33","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"43","author":"Vahanian","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib34","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib35","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/ehjcvp\/pvab083","article-title":"Fast vs. ultraslow thrombolytic infusion regimens in patients with obstructive mechanical prosthetic valve thrombosis: a pilot randomized clinical trial","volume":"8","author":"Sadeghipour","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2025.07.061_bib36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00134-024-07382-y","article-title":"British societies guideline on the management of emergencies in implantable left ventricular assist device recipients in transplant centres","volume":"50","author":"Akhtar","year":"2024","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib37","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ejcts\/ezz098","article-title":"2019 EACTS expert consensus on long-term mechanical circulatory support","volume":"56","author":"Potapov","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jacc.2025.07.061_bib38","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000366","article-title":"Management of central retinal artery occlusion: a scientific statement from the American Heart Association","volume":"52","author":"Mac Grory","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.07.061_bib39","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ophtha.2010.03.061","article-title":"Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial","volume":"117","author":"Schumacher","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jacc.2025.07.061_bib40","first-page":"397","article-title":"Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)","volume":"1","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib41","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(88)92656-6","article-title":"Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET)","volume":"2","author":"Wilcox","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib43","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib44","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJM199710163371603","article-title":"A comparison of reteplase with alteplase for acute myocardial infarction","volume":"337","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib45","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1161\/01.CIR.98.25.2805","article-title":"TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators","volume":"98","author":"Cannon","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.061_bib46","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0140-6736(99)07403-6","article-title":"Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial","volume":"354","author":"Van De Werf","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib47","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(17)31441-1","article-title":"Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis","volume":"390","author":"Jinatongthai","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib48","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jacc.2004.07.002","volume":"44","author":"Antman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib49","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ahj.2008.07.029","article-title":"Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006","volume":"156","author":"Gibson","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib50","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.008112","article-title":"Ten-year trends in patient characteristics, treatments, and outcomes in myocardial infarction from National Cardiovascular Data Registry Chest Pain-MI Registry","volume":"15","author":"Gandhi","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2025.07.061_bib51","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/eurheartj\/ehu043","article-title":"German nationwide data on current trends and management of acute myocardial infarction: discrepancies between trials and real-life","volume":"35","author":"Freisinger","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ahj.2019.05.007","article-title":"Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: data from the FAST-MI program 1995-2015","volume":"214","author":"Puymirat","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib53","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/eurheartj\/ehx515","article-title":"Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014","volume":"38","author":"Szummer","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib54","first-page":"573","article-title":"Five-year evolution of reperfusion strategies and early mortality in patients with ST-segment elevation myocardial infarction in France","volume":"6","author":"El Khoury","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jacc.2025.07.061_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081301","article-title":"Exploring variation in timely reperfusion treatment in ST-segment elevation myocardial infarction in Norway: a national register-based cohort study","volume":"14","author":"Uleberg","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2025.07.061_bib56","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004202","article-title":"Contemporary trends and age-specific sex differences in management and outcome for patients with ST-segment elevation myocardial infarction","volume":"5","author":"De Luca","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.07.061_bib57","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.hlc.2018.05.191","article-title":"ST-elevation acute myocardial infarction in Australia\u2014temporal trends in patient management and outcomes 1999\u20132016","volume":"28","author":"Aliprandi-Costa","year":"2019","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jacc.2025.07.061_bib58","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.amjcard.2013.11.024","article-title":"Utilization of evidence-based therapy for acute coronary syndrome in high-income and low\/middle-income countries","volume":"113","author":"Shimony","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib59","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ahj.2011.07.029","article-title":"Management of acute coronary syndromes in developing countries: acute coronary events\u2013a multinational survey of current management strategies","volume":"162","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib60","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/CIRCULATIONAHA.106.638353","article-title":"Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy","volume":"114","author":"Pinto","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.061_bib61","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/CIRCULATIONAHA.111.018549","article-title":"Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase","volume":"124","author":"Pinto","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.061_bib62","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa1301092","article-title":"Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction","volume":"368","author":"Armstrong","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib63","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/CIRCULATIONAHA.123.064521","article-title":"STREAM-2: half-dose tenecteplase or primary percutaneous coronary intervention in older patients with ST-segment-elevation myocardial infarction: a randomized, open-label trial","volume":"148","author":"Van de Werf","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.061_bib64","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/01.CIR.93.5.857","article-title":"Fibrin-selective thrombolytic therapy for acute myocardial infarction","volume":"93","author":"Collen","year":"1996","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacc.2025.07.061_bib65","doi-asserted-by":"crossref","first-page":"e013455","DOI":"10.1161\/CIRCINTERVENTIONS.123.013455","article-title":"Single bolus r-SAK before primary PCI for ST-segment-elevation myocardial infarction","volume":"17","author":"Chen","year":"2024","journal-title":"Circ Cardiovasc Interv"},{"issue":"15","key":"10.1016\/j.jacc.2025.07.061_bib66","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/heartjnl-2024-324078","article-title":"Intracoronary thrombolysis in ST-elevation myocardial infarction: a systematic review and meta-analysis","volume":"110","author":"Rehan","year":"2024","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2025.07.061_bib67","first-page":"1606","article-title":"Phase 2 results. A cooperative study","volume":"229","year":"1974","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib68","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01062714","article-title":"Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial","volume":"2","author":"Jerjes-Sanchez","year":"1995","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2025.07.061_bib69","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/eurheartj\/ehu218","article-title":"Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis","volume":"36","author":"Marti","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib70","first-page":"CD004437","article-title":"Thrombolytic therapy for pulmonary embolism","volume":"4","author":"Zuo","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.07.061_bib71","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2014.5990","article-title":"Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis","volume":"311","author":"Chatterjee","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib72","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jacc.2024.07.044","article-title":"International clinical practice guideline recommendations for acute pulmonary embolism: harmony, dissonance, and silence","volume":"84","author":"Zuin","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib73","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive Summary: Antithrombotic therapy for VTE disease: Second Update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2025.07.061_bib74","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jtha.2024.09.035","article-title":"Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE","volume":"23","author":"Kirienko","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2025.07.061_bib75","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa1302097","article-title":"Fibrinolysis for patients with intermediate-risk pulmonary embolism","volume":"370","author":"Meyer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib76","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jcin.2018.04.008","article-title":"A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial","volume":"11","author":"Tapson","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2025.07.061_bib77","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jcin.2015.04.020","article-title":"A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II Study","volume":"8","author":"Piazza","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2025.07.061_bib78","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jcin.2021.04.049","article-title":"Randomized trial comparing standard versus ultrasound-assisted thrombolysis for submassive pulmonary embolism: the SUNSET sPE trial","volume":"14","author":"Avgerinos","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2025.07.061_bib79","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.4244\/EIJ-D-21-01080","article-title":"A pilot randomised trial of catheter-directed thrombolysis or standard anticoagulation for patients with intermediate-high risk acute pulmonary embolism","volume":"18","author":"Kroupa","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2025.07.061_bib80","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.amjcard.2012.09.027","article-title":"Moderate pulmonary embolism treated with thrombolysis (from the \"MOPETT\" Trial)","volume":"111","author":"Sharifi","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2022.05.011","article-title":"Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: rationale and design of the HI-PEITHO study","volume":"251","author":"Klok","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib82","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ahj.2024.11.016","article-title":"Rationale and design of the PE-TRACT trial: a multicenter randomized trial to evaluate catheter-directed therapy for the treatment of intermediate-risk pulmonary embolism","volume":"281","author":"Sista","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib83","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1055\/a-1653-4699","article-title":"Reduced-dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism: rationale and design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial","volume":"122","author":"Sanchez","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2025.07.061_bib84","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1161\/CIRCULATIONAHA.124.072364","article-title":"Large-bore mechanical thrombectomy versus catheter-directed thrombolysis in the management of intermediate-risk pulmonary embolism: primary results of the PEERLESS randomized controlled trial","volume":"151","author":"Jaber","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.061_bib85","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","article-title":"The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"130","author":"Kahn","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.061_bib86","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/asheducation-2016.1.413","article-title":"The post-thrombotic syndrome","volume":"2016","author":"Kahn","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jacc.2025.07.061_bib87","article-title":"Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb","volume":"1","author":"Broderick","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.07.061_bib88","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)61753-4","article-title":"Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial","volume":"379","author":"Enden","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib89","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2352-3026(19)30209-1","article-title":"Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial","volume":"7","author":"Notten","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jacc.2025.07.061_bib90","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ejvs.2021.10.058","article-title":"Treatment strategies for proximal deep vein thrombosis: a network meta-analysis of randomised controlled trials","volume":"63","author":"Ashrafi","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jacc.2025.07.061_bib91","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.jcin.2018.04.048","article-title":"Contemporary trends and comparative outcomes with adjunctive inferior vena cava filter placement in patients undergoing catheter-directed thrombolysis for deep vein thrombosis in the United States: insights from the national inpatient sample","volume":"11","author":"Akhtar","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2025.07.061_bib92","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jama.1995.03530130023023","article-title":"Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)","volume":"274","author":"Hacke","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib93","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib94","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.282.21.2019","article-title":"Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke","volume":"282","author":"Clark","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib95","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(04)15692-4","article-title":"Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials","volume":"363","author":"Hacke","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib96","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib97","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1941874415583116","article-title":"Intravenous thrombolysis for acute ischemic stroke within 3 hours versus between 3 and 4.5 hours of symptom onset","volume":"5","author":"Cheng","year":"2015","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.jacc.2025.07.061_bib98","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/S0140-6736(12)60768-5","article-title":"The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third International Stroke Trial [IST-3]): a randomised controlled trial","volume":"379","author":"Sandercock","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib99","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.annemergmed.2012.12.008","article-title":"rt-PA and stroke: does IST-3 make it all clear or muddy the waters? Answers to the November 2012 Journal Club questions","volume":"61","author":"Radecki","year":"2013","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib100","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/jhm.689","article-title":"Trends in thrombolytic use for ischemic stroke in the United States","volume":"5","author":"Fang","year":"2010","journal-title":"J Hosp Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib101","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/STROKEAHA.120.032132","article-title":"Ten-year trend in age, sex, and racial disparity in tpa (alteplase) and thrombectomy use following stroke in the United States","volume":"52","author":"Otite","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.07.061_bib102","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/CIRCOUTCOMES.111.000095","article-title":"Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals","volume":"6","author":"Schwamm","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2025.07.061_bib103","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCULATIONAHA.108.783688","article-title":"Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack","volume":"119","author":"Schwamm","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.061_bib104","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1161\/STROKEAHA.110.612358","article-title":"Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years","volume":"42","author":"Adeoye","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.07.061_bib105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamaneurol.2021.5321","article-title":"Comparison of mobile stroke unit with usual care for acute ischemic stroke management: a systematic review and meta-analysis","volume":"79","author":"Turc","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib106","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1474-4422(22)00519-1","article-title":"Thrombolysis for acute ischaemic stroke: current status and future perspectives","volume":"22","author":"Tsivgoulis","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib107","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa1716405","article-title":"Tenecteplase versus alteplase before thrombectomy for ischemic stroke","volume":"378","author":"Campbell","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib108","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1474-4422(24)00206-0","article-title":"Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial","volume":"23","author":"Parsons","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/svn-2021-000978","article-title":"Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study","volume":"7","author":"Li","year":"2022","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib110","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","article-title":"Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial","volume":"401","author":"Wang","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib111","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(22)00171-5","article-title":"Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial","volume":"21","author":"Bivard","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib112","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S1474-4422(15)70017-7","article-title":"Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study","volume":"14","author":"Huang","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib113","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/STROKEAHA.109.572040","article-title":"Phase IIB\/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial","volume":"41","author":"Haley","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.07.061_bib114","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa1109842","article-title":"A randomized trial of tenecteplase versus alteplase for acute ischemic stroke","volume":"366","author":"Parsons","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib115","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/jama.2024.14721","article-title":"Tenecteplase vs alteplase for patients with acute ischemic stroke: the ORIGINAL randomized clinical trial","volume":"332","author":"Meng","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib116","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1474-4422(22)00124-7","article-title":"Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial","volume":"21","author":"Kvistad","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib117","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","article-title":"Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial","volume":"16","author":"Logallo","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib118","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","article-title":"Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial","volume":"400","author":"Menon","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib119","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209903","article-title":"Tenecteplase vs alteplase in acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis of randomized trials","volume":"103","author":"Palaiodimou","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2025.07.061_bib122","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1056\/NEJMoa2400314","article-title":"Reteplase versus alteplase for acute ischemic stroke","volume":"390","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib123","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1474-4422(21)00210-6","article-title":"Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4\u00b75 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial","volume":"20","author":"Gusev","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib124","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(24)00436-8","article-title":"Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4\u00b75 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial","volume":"24","author":"Li","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib125","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.25415","article-title":"Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset: a phase 3 randomized clinical trial","volume":"6","author":"Song","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.07.061_bib126","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMoa1813046","article-title":"Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke","volume":"380","author":"Ma","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib127","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1804355","article-title":"MRI-guided thrombolysis for stroke with unknown time of onset","volume":"379","author":"Thomalla","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(22)00484-7","article-title":"Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial","volume":"22","author":"Roaldsen","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib129","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamaneurol.2024.4688","article-title":"Prourokinase vs standard care for patients with mild ischemic stroke: the PUMICE randomized clinical trial","volume":"82","author":"Xiong","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib130","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/S0140-6736(24)00921-8","article-title":"Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial","volume":"403","author":"Coutts","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib131","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2018.8496","article-title":"Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: the PRISMS randomized clinical trial","volume":"320","author":"Khatri","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib132","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1001\/jama.2023.7827","article-title":"Dual antiplatelet therapy vs alteplase for patients with minor nondisabling acute ischemic stroke: the ARAMIS randomized clinical trial","volume":"329","author":"Chen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib133","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/23969873221076968","volume":"7","author":"Turc","year":"2022","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.jacc.2025.07.061_bib134","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.282.21.2003","article-title":"Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial","volume":"282","author":"Furlan","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.wnsx.2024.100316","article-title":"Efficacy and safety of local fibrinolytic therapy in intracranial hemorrhages: a systematic review and meta-analysis of randomised controlled trials","volume":"22","author":"Rajeswaran","year":"2024","journal-title":"World Neurosurg X"},{"key":"10.1016\/j.jacc.2025.07.061_bib136","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(19)30195-3","article-title":"Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial","volume":"393","author":"Hanley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib137","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(16)32410-2","article-title":"Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial","volume":"389","author":"Hanley","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.061_bib138","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00000658-199409000-00003","article-title":"Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial","volume":"220","year":"1994","journal-title":"Ann Surg"},{"key":"10.1016\/j.jacc.2025.07.061_bib139","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM199804163381603","article-title":"A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators","volume":"338","author":"Ouriel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib140","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0741-5214(94)70214-4","article-title":"A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia","volume":"19","author":"Ouriel","year":"1994","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jacc.2025.07.061_bib141","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0950-821X(05)80239-7","article-title":"Surgical treatment versus thrombolysis in acute arterial occlusion: a randomised controlled study","volume":"6","author":"Nilsson","year":"1992","journal-title":"Eur J Vasc Surg"},{"key":"10.1016\/j.jacc.2025.07.061_bib142","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0741-5214(05)80036-9","article-title":"Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators","volume":"23","author":"Ouriel","year":"1996","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jacc.2025.07.061_bib143","first-page":"CD002784","article-title":"Surgery versus thrombolysis for initial management of acute limb ischaemia","volume":"8","author":"Darwood","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.07.061_bib144","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1708538118797782","article-title":"Contemporary trends and outcomes of thrombolytic therapy for acute lower extremity ischemia","volume":"27","author":"Bath","year":"2019","journal-title":"Vascular"},{"key":"10.1016\/j.jacc.2025.07.061_bib145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejvs.2019.09.006","article-title":"Editor's Choice: European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia","volume":"59","author":"Bjorck","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jacc.2025.07.061_bib146","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1526602814566578","article-title":"Dutch randomized trial comparing standard catheter-directed thrombolysis and ultrasound-accelerated thrombolysis for arterial thromboembolic infrainguinal disease (DUET)","volume":"22","author":"Schrijver","year":"2015","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.jacc.2025.07.061_bib147","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1055\/s-0038-1648911","article-title":"Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial","volume":"72","author":"Haire","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2025.07.061_bib148","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S1051-0443(07)61575-9","article-title":"Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial\u2013the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial","volume":"12","author":"Ponec","year":"2001","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib149","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2002.20.1.317","article-title":"Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial","volume":"20","author":"Deitcher","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacc.2025.07.061_bib150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/01.RVI.0000106385.63463.EC","article-title":"Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer","volume":"15","author":"Liu","year":"2004","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib151","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1051-0443(07)61965-4","article-title":"Treatment of occluded central venous catheters with alteplase: results in 1,064 patients","volume":"13","author":"Semba","year":"2002","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib152","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacc.2025.07.061_bib153","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib154","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/eurheartj\/ehs486","article-title":"Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies","volume":"34","author":"Karthikeyan","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib155","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jcmg.2012.10.016","article-title":"Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial","volume":"6","author":"\u00d6zkan","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.07.061_bib156","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ahj.2015.04.025","article-title":"Ultraslow thrombolytic therapy: a novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: the Ultra-slow PROMETEE trial","volume":"170","author":"\u00d6zkan","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132507","article-title":"Ultraslow low-dose thrombolytic therapy in patients with acute mechanical prosthetic heart valve thrombosis: a prospective cohort study","volume":"416","author":"Sadeghipour","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib158","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jacc.2021.12.027","article-title":"Thrombolysis or surgery in patients with obstructive mechanical valve thrombosis: the multicenter HATTUSHA Study","volume":"79","author":"\u00d6zkan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib159","article-title":"Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial","volume":"27","author":"Karthikeyan","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib160","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1161\/01.CIR.72.1.112","article-title":"Lysis of left ventricular thrombi with urokinase","volume":"72","author":"Kremer","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.061_bib161","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/0028-3886.60419","article-title":"Cardioembolic stroke on unaffected side during thrombolysis for acute ischemic stroke","volume":"58","author":"Garg","year":"2010","journal-title":"Neurol India"},{"key":"10.1016\/j.jacc.2025.07.061_bib162","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association","volume":"146","author":"Levine","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.061_bib163","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jacc.2022.01.011","article-title":"Left ventricular thrombus following acute myocardial infarction: JACC State-of-the-Art Review","volume":"79","author":"Camaj","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib164","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4244\/EIJ-D-24-00527","article-title":"Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials","volume":"21","author":"Jenab","year":"2025","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2025.07.061_bib165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.healun.2013.11.001","article-title":"Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device","volume":"33","author":"Kirklin","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2025.07.061_bib166","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.healun.2013.12.001","article-title":"An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial","volume":"33","author":"Najjar","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2025.07.061_bib167","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.969766","article-title":"Systemic thrombolysis in the management of pump thrombosis in patients with left ventricular assist devices","volume":"9","author":"Kortekaas","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib168","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/MAT.0000000000000340","article-title":"Systemic thrombolysis versus device exchange for pump thrombosis management: a single-center experience","volume":"62","author":"Oezpeker","year":"2016","journal-title":"ASAIO J"},{"key":"10.1016\/j.jacc.2025.07.061_bib169","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.athoracsur.2011.12.024","article-title":"Successful treatment of early thrombosis of HeartWare left ventricular assist device with intraventricular thrombolytics","volume":"94","author":"Kamouh","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2025.07.061_bib170","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.healun.2024.04.065","article-title":"An ISHLT consensus statement on strategies to prevent and manage hemocompatibility related adverse events in patients with a durable, continuous-flow ventricular assist device","volume":"43","author":"Hollis","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2025.07.061_bib171","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajo.2005.03.038","article-title":"Central retinal artery occlusion: visual outcome","volume":"140","author":"Hayreh","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jacc.2025.07.061_bib172","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1161\/STROKEAHA.111.613653","article-title":"Efficacy of intravenous tissue-type plasminogen activator in central retinal artery occlusion: report from a randomized, controlled trial","volume":"42","author":"Chen","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.07.061_bib173","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000366","article-title":"Management of central retinal artery occlusion: a scientific statement from the American Heart Association","volume":"52","author":"Mac Grory","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.07.061_bib174","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ophtha.2010.03.061","article-title":"Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial","volume":"117","author":"Schumacher","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jacc.2025.07.061_bib175","first-page":"CD002005","article-title":"Anticoagulation for cerebral venous sinus thrombosis","volume":"2011","author":"Coutinho","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.07.061_bib176","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/15910199221143418","article-title":"Safety and efficacy of endovascular thrombolysis in patients with acute cerebral venous sinus thrombosis: a systematic review","volume":"30","author":"Paybast","year":"2024","journal-title":"Interv Neuroradiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib177","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/01.STR.0000117571.76197.26","article-title":"Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)","volume":"35","author":"Ferro","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.07.061_bib178","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/jamaneurol.2020.1022","article-title":"Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT randomized clinical trial","volume":"77","author":"Coutinho","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib179","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1161\/STR.0000000000000456","article-title":"Diagnosis and management of cerebral venous thrombosis: a scientific statement from the American Heart Association","volume":"55","author":"Saposnik","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.07.061_bib180","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1001\/jamainternmed.2014.4758","article-title":"Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines","volume":"174","author":"Sardar","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib181","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaneurol.2021.0873","article-title":"Sex disparities in enrollment in recent randomized clinical trials of acute stroke: a meta-analysis","volume":"78","author":"Strong","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacc.2025.07.061_bib182","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033467","article-title":"Disparities in race and ethnicity reporting and representation for clinical trials in stroke: 2010 to 2020","volume":"13","author":"Nanavati","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.07.061_bib183","doi-asserted-by":"crossref","first-page":"e944","DOI":"10.1161\/CIR.0000000000001306","article-title":"Disparities in current pulmonary embolism management and outcomes: a scientific statement from the American Heart Association","volume":"151","author":"Takahashi","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.061_bib184","doi-asserted-by":"crossref","first-page":"e782","DOI":"10.1161\/STROKEAHA.121.035220","article-title":"Geographic and regional variability in racial and ethnic disparities in stroke thrombolysis in the United States","volume":"52","author":"Suolang","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.07.061_bib185","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/STROKEAHA.116.015056","article-title":"Individual and system contributions to race and sex disparities in thrombolysis use for stroke patients in the United States","volume":"48","author":"Faigle","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2025.07.061_bib186","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/CIRCULATIONAHA.108.789800","article-title":"Sex differences in medical care and early death after acute myocardial infarction","volume":"118","author":"Jneid","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.061_bib187","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.608899","article-title":"Alpha2-antiplasmin: the devil you don't know in cerebrovascular and cardiovascular disease","volume":"7","author":"Singh","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib188","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073670","article-title":"Thrombin Activatable Fibrinolysis Inhibitor (TAFI): an updated narrative review","volume":"22","author":"Sillen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.07.061_bib189","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/ATVBAHA.107.157479","article-title":"Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis","volume":"28","author":"Izuhara","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.07.061_bib190","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2014-07-588319","article-title":"Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke","volume":"125","author":"Wyseure","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2025.07.061_bib191","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1016\/j.jtha.2023.04.037","article-title":"Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study","volume":"21","author":"Vanassche","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2025.07.061_bib192","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202001647","article-title":"Thrombolytic agents: nanocarriers in controlled release","volume":"16","author":"Hassanpour","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.jacc.2025.07.061_bib193","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41536-022-00230-x","article-title":"Therapeutic use of \u03b12-antiplasmin as an antifibrinolytic and hemostatic agent in surgery and regenerative medicine","volume":"7","author":"Liu","year":"2022","journal-title":"NPJ Regen Med"},{"key":"10.1016\/j.jacc.2025.07.061_bib194","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212537","article-title":"Fibrinogen and antifibrinolytic proteins: interactions and future therapeutics","volume":"22","author":"Pechlivani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.07.061_bib195","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/med.21315","article-title":"Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders","volume":"34","author":"Al-Horani","year":"2014","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jacc.2025.07.061_bib196","doi-asserted-by":"crossref","first-page":"S501","DOI":"10.1161\/CIR.0000000000000264","article-title":"Part 10: Special circumstances of resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care","volume":"132","author":"Lavonas","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2025.07.061_bib197","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib198","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2018.09.013","article-title":"Trends in catheter-directed thrombolysis and systemic thrombolysis for the treatment of pulmonary embolism","volume":"207","author":"Adusumalli","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2025.07.061_bib199","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.amjcard.2022.03.060","article-title":"Contemporary national trends and outcomes of pulmonary embolism in the United States","volume":"176","author":"Sedhom","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib200","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jvir.2019.02.024","article-title":"Nationwide trends in use of catheter-directed therapy for treatment of pulmonary embolism in Medicare beneficiaries from 2004 to 2016","volume":"30","author":"Gayou","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib201","first-page":"711","article-title":"Temporal trends in the utilization of advanced therapies among patients with acute pulmonary embolism: insights from a national database","volume":"12","author":"Abumoawad","year":"2023","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"22","key":"10.1016\/j.jacc.2025.07.061_bib202","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.061_bib203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor's Choice: European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"Kakkos","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"24","key":"10.1016\/j.jacc.2025.07.061_bib204","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 5","key":"10.1016\/j.jacc.2025.07.061_bib205","doi-asserted-by":"crossref","first-page":"v152","DOI":"10.1093\/annonc\/mdv296","article-title":"Central venous access in oncology: ESMO Clinical Practice Guidelines","volume":"26","author":"Sousa","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jacc.2025.07.061_bib206","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015186","article-title":"Comparison of reperfusion strategies for ST-segment-elevation myocardial infarction: a multivariate network meta-analysis","volume":"9","author":"Fazel","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.07.061_bib207","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2024.0589","article-title":"Time to treatment with intravenous thrombolysis before thrombectomy and functional outcomes in acute ischemic stroke: a meta-analysis","volume":"331","author":"Kaesmacher","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.07.061_bib208","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/STROKEAHA.124.048536","article-title":"Thrombolysis for ischemic stroke beyond the 4.5-hour window: a meta-analysis of randomized clinical trials","volume":"56","author":"G\u00fcnkan","year":"2025","journal-title":"Stroke"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725074297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725074297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:27:17Z","timestamp":1791451637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725074297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":206,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0735109725074297"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.07.061","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibrinolytic Therapy for Thromboembolic Diseases","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.07.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}